Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
10-K

Annual report which provides a comprehensive overview of the company for the past year

 View HTML
0001558370-19-001094.pdf
0001558370-19-001094.rtf
0001558370-19-001094.xls
EX-101.INS - EX-101.INS
S-8

Securities offered to employees pursuant to employee benefit plans

 View HTML
0001558370-19-001099.pdf
0001558370-19-001099.rtf
0001558370-19-001099.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000080255-19-002675.pdf
0000080255-19-002675.rtf
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000315066-19-000901.pdf
0000315066-19-000901.rtf
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0001193125-19-037923.pdf
0001193125-19-037923.rtf
0001193125-19-037923.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000902219-19-000142.pdf
0000902219-19-000142.rtf
0000902219-19-000142.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000932471-19-004984.pdf
0000932471-19-004984.rtf
0000932471-19-004984.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-19-000364.pdf
0001558370-19-000364.rtf
0001558370-19-000364.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000215457-19-003235.pdf
0000215457-19-003235.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-19-000064.pdf
0001558370-19-000064.rtf
0001558370-19-000064.xls